Rehabilitation program for lung cancer patients
Official title: Cross-sectorial Rehabilitation of Patients with Lung Cancer
Run by Copenhagen University Hospital at Herlev · NCT06705465 · Data updated 2026-11-12
This study is testing a new way to help lung cancer patients get involved in rehabilitation programs earlier to see if it improves their physical abilities and quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Copenhagen University Hospital at Herlev Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Herlev, Denmark) |
| Status | Recruiting |
| Started | October 7, 2024 |
| Main results expected | July 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | December 18, 2024 |
| Trial ID | NCT06705465 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with non-small cell lung cancer who are undergoing their first line of systemic treatment.
✕Probably not a fit
Patients who cannot communicate in Danish or are cognitively unfit to provide consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to improve the participation of lung cancer patients in rehabilitation programs through an 'early contact conference' approach. It involves collaboration between the Department of Oncology and municipal rehabilitation services, utilizing video conferencing to facilitate communication. The study will assess whether this intervention enhances patients' physical abilities and quality of life. Thirteen municipalities in Region Hovedstaden will participate in this cluster randomized controlled trial, focusing on patients diagnosed with non-small cell lung cancer (NSCLC) undergoing systemic treatment.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and physical capabilities of lung cancer patients through better access to rehabilitation services.
How similar studies have gone: Other studies have shown promising results with similar rehabilitation approaches, indicating potential for success in this novel intervention.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients diagnosed with NSCLC * 1\. line systemic treatment Exclusion Criteria: * cannot speak, understand, and/or read Danish * cognitive/psychologically unfit to give consent
Where it's running
-
Herlev and Gentofte Hospital
Herlev, Denmark, Denmark Recruiting
Study contacts
- Study coordinator: Camilla S Balle, PhD student
- Email: camilla.sick.balle@regionh.dk
- Phone: +45 51332047
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EGFR-TKIs plus PD-1 antibody in first-line EGFR-mutant NSCLC
This study tests whether adding a PD-1 antibody to a first-line EGFR-TKI helps people with EGFR-mutant advanced NSCLC see longer progression-free survival.
-
Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations
This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.
-
Combination of immunotherapy and surgery for advanced lung cancer
This study is testing if a new combination of immunotherapy and surgery can help people with advanced lung cancer live longer and healthier compared to current treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.